X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recognizing National Glaucoma Awareness Month

By Matthew Norawong  |    February 1, 2023
January was National Glaucoma Awareness Month and provided us an opportunity to spread the word and honor the millions of patients around the world who are impacted by this debilitating disease.   ...   Read More

In their own words: Insured Americans support policy reforms that address access and affordability concerns

By Tom Wilbur  |    December 14, 2022
A survey of more than 5,000 Americans conducted with Ipsos found that insured Americans want better health care coverage. These insights come from the third installment of the Patient Experience...   Read More

Navigating the patient experience: Burdens and barriers standing between patients and their care

By Mark Keida  |    September 12, 2022
Health care affordability is not the only hurdle facing patients, according to PhRMA’s third Patient Experience Survey (PES). The latest PES report exposes another crucial problem: the frustration...   Read More

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

By Nicole Longo  |    August 10, 2022
Last weekend, the Senate passed the Inflation Reduction Act which includes dangerous price-setting provisions. The bill now heads to the House for consideration, where it is not too late for them to...   Read More

Myth vs. Fact: The Senate’s latest price setting proposal

By Nicole Longo  |    August 5, 2022
The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t...   Read More

ICYMI: Patients across the country are sharing concerns about government price setting

By Matthew Norawong  |    August 3, 2022
As members of Congress continue to push forward misguided government price-setting policies under the guise of “negotiation,” patient advocates across the country have been speaking out in local...   Read More

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

By Brian Newell  |    August 1, 2022
A new analysis by the health care analytics and research firm Avalere reveals the partisan drug pricing bill will have a much deeper impact on the biopharmaceutical research industry than previously...   Read More

ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill

By Brian Newell  |    July 29, 2022
During a widely attended media briefing, physicians, biopharmaceutical leaders, and a brave cancer survivor, all expressed their strong opposition to the extreme drug pricing bill Congress is...   Read More

The Patient Perspective: Government price-setting harms patients

By Andrew Powaleny  |    July 22, 2022
Unfortunately, policymakers are again looking for bumper-sticker answers to the health care affordability challenges many Americans face, ignoring real commonsense solutions in exchange for flawed...   Read More

Spotlighting a growing mental health challenge

By Anne McDonald Pritchett, PhD  |    May 9, 2022
During the pandemic, about four in 10 American adults have reported symptoms of anxiety or depressive disorder. This share is up from one in 10 adults reporting symptoms prior to the pandemic....   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates